Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder

NCT02557971 · clinicaltrials.gov ↗

COMPLETED

Status

315

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder, Overactive

Interventions

DRUG: onabotulinumtoxinA

Sponsor

Allergan